TICEBA

Stem Cell Experts

Making a difference with ABCB5

About Us

National marketing authorization in Germany for novel cell therapy

Our daughter company RHEACELL has been granted national marketing authorization (§4b of the German Medicinal Products Act) in Germany for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.

TICEBA: stem cell pioneer and expert - navigating hitherto unchartered waters

Drawing on over 15 years' experience in advanced stem cell research and regenerative medicine to pioneer the production of ABCB5-positive (ABCB5+) mesenchymal stem cells and innovative treatment pathways.

GMP production

Using cutting-edge, in-house process technology and quality control systems to generate state-of-the-art ABCB5+ mesenchymal stem cells ("H.F.M Stem Cells") and ATMP (Advanced Therapy Medicinal Products) in line with AMG (German Medicinal Products Act) requirements.

Translational medicine: from in-house potency assay to clinical efficacy

Science-based mechanisms-of-action translated into GMP-validated potency assays and release criteria to predict clinical efficacy.

Off-the-shelf & ready to use: serving market needs

High through-put stem cell production based on globally patented technology and expertise - catering for world-wide market needs - anytime, anyplace, anywhere.

Clinical development pipeline and established technology platform focusing on rare diseases and more

Our tried and tested patented technology platform nurturing next-generation technologies (CRISPR/Cas, iPS Technology and 3D Bioprinting), heralding the arrival of next-generation cell therapies.

ABCB5 patents – a world-wide exclusive

TICEBA - exclusive licensee of the full ABCB5 patent portfolio from Boston Children's Hospital - a teaching affiliate of Harvard Medical School, Boston, Massachusetts. Several of these were invented at the same time and are jointly owned by TICEBA.

TICEBA history

2000

First ABCB5 patent

2003

First description of ABCB5+ cells and creation of TICEBA

2005

TICEBA launches business activities

2009

Approval granted for tissue procurement and processing

2012

Creation of RHEACELL

2014

Manufacturing license granted (AMG – German Medicinal Products Act)

2016

First clinical trial using ABCB5+ cells

2019

Technology platform patent granted ("H.F.M Stem Cells")

2020

National marketing authorization applied for in Germany

2021

Pediatric Investigation Plan (PIP) approved by PDCO (EMA) for RHEACELL

2021

National marketing authorization in Germany granted for AMESANAR®

Production

Production

State-of-the art clean room facility meeting current international standards.

TO FIND OUT MORE
Quality Control

Quality Control

A stringent quality control procedure is the hallmark of guaranteed product safety and quality in line with international GMP standards. Every product batch meets standardized, validated in-house release criteria.

TO FIND OUT MORE
Quality Assurance

Quality Assurance

Satisfying regulatory and legislative requirements and fine-tuning the Quality Assurance program to guarantee GMP-compliant processes.

TO FIND OUT MORE